Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors
Cives M, Kunz P, Morse B, Coppola D, Schell M, Campos T, Nguyen P, Nandoskar P, Khandelwal V, Strosberg J. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocrine Related Cancer 2014, 22: 1-9. PMID: 25376618, PMCID: PMC4643672, DOI: 10.1530/erc-14-0360.Peer-Reviewed Original ResearchConceptsProgression-free survivalOverall radiographic response rateOverall survivalPasireotide LARSomatostatin analoguesFirst-line systemic agentMedian progression-free survivalPhase II clinical trialGrade 3 hyperglycemiaMetastatic grade 1Neuroendocrine tumor growthPrevious systemic therapyRadiographic response rateRates of hyperglycemiaGrade 3/4 toxicitiesMedian overall survivalMetastatic neuroendocrine tumorsPhase II studySolid Tumors criteriaTreatment-naïve patientsHepatic tumor burdenResponse Evaluation CriteriaNovel somatostatin analogReceptor subtype 1LAR treatmentPhase II clinical trial of pasireotide LAR in patients with metastatic neuroendocrine tumors.
Strosberg J, Jump H, Valone T, Weber J, Khandelwal V, Kunz P. Phase II clinical trial of pasireotide LAR in patients with metastatic neuroendocrine tumors. Journal Of Clinical Oncology 2014, 32: 241-241. DOI: 10.1200/jco.2014.32.3_suppl.241.Peer-Reviewed Original ResearchPasireotide LARSomatostatin analoguesMedian PFSLong-term insulin therapySomatostatin receptor subtypes 1Phase II clinical trialBest radiographic responseGrade 3 hyperglycemiaPrior systemic therapyRates of hyperglycemiaYear OS ratesTreatment-naïve patientsMetastatic neuroendocrine tumorsPhase II trialIntermediate-grade tumorsNovel somatostatin analogReceptor subtype 1LAR treatmentQ4 weeksStable diseaseII trialNaïve patientsPrimary endpointRefractory patientsInsulin therapy